Tesamorelin Research for Visceral Fat Reduction
An evidence-based overview of research examining Tesamorelin in the context of visceral fat reduction. This page synthesizes findings from peer-reviewed literature.
Research Summary
In adults with HIV-associated lipodystrophy, VAT is the directly studied and approved endpoint. The 2007 pivotal trial reported -15.2% versus +5.0% VAT change at 26 weeks; the other pivotal trial reported -10.9% versus -0.6%. Abdominal subcutaneous fat did not change significantly in the pooled trial. A separate small study in 60 abdominally obese adults with reduced GH secretion also reported a VAT difference, but does not establish a general obesity indication or long-term cardiovascular benefit.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.